A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (Multicentrické, odslepené predĺžené skúšanie 3. fázy, perorálne podávaného RPC1063 pri liečbe stredne závažnej až závažnej ulceróznej kolitídy)

Trial Profile

A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis (Multicentrické, odslepené predĺžené skúšanie 3. fázy, perorálne podávaného RPC1063 pri liečbe stredne závažnej až závažnej ulceróznej kolitídy)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Celgene Corporation; Receptos
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 25 Dec 2020 to 30 Sep 2020.
    • 20 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 27 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top